Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JNJ-67856633 is an orally active, first-in-class, potent, selective and allosteric inhibitor of MALT1 protease . JNJ-67856633 lead to tumor stasis in some cases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 48.00 | |
2 mg | In stock | $ 68.00 | |
5 mg | In stock | $ 113.00 | |
10 mg | In stock | $ 189.00 | |
25 mg | In stock | $ 363.00 | |
50 mg | In stock | $ 563.00 | |
100 mg | In stock | $ 791.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 117.00 |
Description | JNJ-67856633 is an orally active, first-in-class, potent, selective and allosteric inhibitor of MALT1 protease . JNJ-67856633 lead to tumor stasis in some cases. |
In vitro | JNJ-67856633 is effective and highly bioavailable in both mouse and rat tumors, and in some cases led to tumor stasis. JNJ-67856633 results in potent in vivo pharmacodynamic shutdown in CD79b- as well as CARD11-mutant ABC-DLBCL models as measured by serum IL10 or uncleaved BCL10 levels in tumors[1][3]. |
In vivo | Dose dependent inhibition of the generation of Tregs (CD4+CD25+FoxP3+) following CD3/28 stimulation was observed upon treatment with JNJ-67856633 suggesting a potential immune modulatory role of MALT1 inhibition[3]. |
Molecular Weight | 467.32 |
Formula | C20H11F6N5O2 |
CAS No. | 2230273-76-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (267.48 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JNJ-67856633 2230273-76-2 Immunology/Inflammation MALT inhibit active allosteric orally selective mucosa associated lymphoid tissue lymphoma translocation gene 1 Inhibitor JNJ67856633 MALT1 potent JNJ 67856633 inhibitor